Alere redoubles efforts with Organization of African First Ladies Against HIV/AIDS

Alere said this week that it is redoubling its commitment to support the Organization of African First Ladies Against HIV/AIDS (OAFLA).

Alere, a global leader in rapid diagnostics, aims to help reduce the impact of HIV/AIDS in Africa, specifically mother-to-child transmission. OAFLA and Alere want to increase early infant diagnosis (EID). In sub-Saharan Africa, 260,000 African children are infected with HIV each year, with many acquiring the virus through breastfeeding from an already infected mother.

"OAFLA is committed to addressing the unfinished business of the Millennium Development Goals, both in terms of advocacy and program delivery, and this can be achieved only through partnerships with governments, NGOs (nongovernmental organizations), the private sector and other stakeholders," Dr. Nana Lordina Dramani Mahama, first lady of the Republic of Ghana and OAFLA's president, said. "Alere has already provided test kits to help us screen 200,000 people for HIV and syphilis infections, and we are delighted that this productive relationship continues to grow and thrive."
"We are honored to provide affordable, point-of-care diagnostics spanning the HIV continuum of care to support OAFLA's efforts to end mother-to-child HIV infections, as well as to identify HIV-infected infants and link them to lifesaving treatment," Namal Nawana, CEO and president of Alere, said. "At Alere, we believe that 'Knowing Now Matters' when it comes to diagnosing HIV. Our partnership with OAFLA is crucial toward achieving this vision by helping more people know their HIV status and linking infected individuals of all ages to care."

EID coverage is less than 20 percent of the Global Plan countries, and the World Health Organization has made EID coverage a priority until mother-to-child transmission is eliminated.

Organizations in this Story

Abbott Laboratories

Want to get notified whenever we write about Abbott Laboratories ?
Next time we write about Abbott Laboratories, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.